关于靶向严重急性呼吸综合征冠状病毒（SARS-CoV）抑制剂的M的最新研究综述。
A review of the latest research on M targeting SARS-COV inhibitors.
作者信息
Yang Huihui, Yang Jinfei
机构信息
Medical School Institute of Reproductive Medicine, Nantong University Nantong 226019 China
Institute of Modern Rehabilitation, University of Health and Rehabilitation Science Qingdao 266001 China
出版信息
RSC Med Chem. 2021 Apr 14;12(7):1026-1036. doi: 10.1039/d1md00066g. eCollection 2021 Jul 21.
Abstract
Since the outbreak of COVID-19, the pandemic caused by SARS-CoV-2 infection is still spreading at an alarming rate and has caused huge loss of life and economic damage worldwide. Although more than one year has passed, effective treatments for COVID-19 and other pathogenic coronaviruses have not yet been developed. Therefore, the development of SARS-CoV-2 inhibitors is an urgent priority. Given that the M sequences of SARS-CoV-2 and SARS-CoV-1 are 100% identical in the catalytic domain for protein cleavage, the viral main protease (M) is one of the most extensive drug targets in all the drug targets being investigated for SARS-CoV-2. To provide scientific researchers with timely anti-SARS-CoV drug development information for M, we focus on the past and current drug design and development strategies for M in this review. We believe that this review will provide meaningful guidance for the design and development of innovative drugs against COVID-19 and other pathogenic coronaviruses in the future.
摘要
自新冠疫情爆发以来，由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染引发的大流行仍在以惊人的速度蔓延，在全球范围内造成了巨大的生命损失和经济破坏。尽管已经过去了一年多时间，但针对新冠病毒和其他致病性冠状病毒的有效治疗方法尚未研发出来。因此，开发SARS-CoV-2抑制剂是当务之急。鉴于SARS-CoV-2与SARS-CoV-1的M序列在蛋白裂解催化结构域中100%相同，病毒主蛋白酶（M）是所有针对SARS-CoV-2研究的药物靶点中最广泛的药物靶点之一。为了及时为科研人员提供针对M的抗SARS-CoV药物开发信息，我们在本综述中重点关注了M过去和当前的药物设计与开发策略。我们相信，本综述将为未来针对新冠病毒和其他致病性冠状病毒的创新药物设计与开发提供有意义的指导。
相似文献
1
A review of the latest research on M targeting SARS-COV inhibitors.关于靶向严重急性呼吸综合征冠状病毒（SARS-CoV）抑制剂的M的最新研究综述。
RSC Med Chem. 2021 Apr 14;12(7):1026-1036. doi: 10.1039/d1md00066g. eCollection 2021 Jul 21.
2
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.SARS-CoV-2 M 抗病毒药物的优化规则：冠状病毒蛋白酶活性位点的整体对接和探索。
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
3
Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug.一种广谱抗冠状病毒药物对SARS-CoV-2主要蛋白酶的抑制作用的结构基础
Am J Cancer Res. 2020 Aug 1;10(8):2535-2545. eCollection 2020.
4
Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.针对 SARS-CoV-2 主蛋白酶的肽模拟抑制剂的共价和非共价结合自由能计算。
Phys Chem Chem Phys. 2021 Mar 21;23(11):6746-6757. doi: 10.1039/d1cp00266j. Epub 2021 Mar 12.
5
Structure-Based Discovery and Structural Basis of a Novel Broad-Spectrum Natural Product against the Main Protease of Coronavirus.基于结构的发现和一种新型广谱天然产物对冠状病毒主要蛋白酶的结构基础。
J Virol. 2022 Jan 12;96(1):e0125321. doi: 10.1128/JVI.01253-21. Epub 2021 Sep 29.
6
Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300.通过半胱氨酸 300 的谷胱甘肽化实现对 SARS-CoV-2 主要蛋白酶的二聚化和活性的调节。
mBio. 2021 Aug 31;12(4):e0209421. doi: 10.1128/mBio.02094-21. Epub 2021 Aug 17.
7
TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）主要蛋白酶（3CLpro）的TAT肽偶联重利用药物：对抗2019冠状病毒病（COVID-19）的潜在治疗干预措施
Arab J Chem. 2020 Nov;13(11):8069-8079. doi: 10.1016/j.arabjc.2020.09.037. Epub 2020 Oct 1.
8
Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Reporter Assay.基于荧光的高通量 SARS-CoV-2 3CL 报告酶测定法的建立。
J Virol. 2020 Oct 27;94(22). doi: 10.1128/JVI.01265-20.
9
Recent Advances in the Discovery of Potent Proteases Inhibitors Targeting the SARS Coronaviruses.新型 SARS 冠状病毒有效蛋白酶抑制剂的研究进展。
Curr Top Med Chem. 2021;21(4):307-328. doi: 10.2174/1568026620999201111160035.
10
2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.2-吡啶酮类天然产物作为 SARS-CoV-2 主蛋白酶抑制剂。
Chem Biol Interact. 2021 Feb 1;335:109348. doi: 10.1016/j.cbi.2020.109348. Epub 2020 Dec 2.
引用本文的文献
1
Molecular docking and molecular dynamics simulation studies of thiazole-coumarin and thiazole-triazole conjugates against M and ACE2 receptor for SARS COV-2.噻唑-香豆素和噻唑-三唑共轭物针对SARS-CoV-2的M和ACE2受体的分子对接及分子动力学模拟研究
In Silico Pharmacol. 2025 Jun 9;13(2):84. doi: 10.1007/s40203-025-00372-y. eCollection 2025.
2
Research Progress on the Structure and Function, Immune Escape Mechanism, Antiviral Drug Development Methods, and Clinical Use of SARS-CoV-2 M.严重急性呼吸综合征冠状病毒2 M蛋白的结构与功能、免疫逃逸机制、抗病毒药物研发方法及临床应用研究进展
Molecules. 2025 Jan 16;30(2):351. doi: 10.3390/molecules30020351.
3
Advances in the Search for SARS-CoV-2 M and PL Inhibitors.新型冠状病毒M和PL抑制剂的研究进展
Pathogens. 2024 Sep 24;13(10):825. doi: 10.3390/pathogens13100825.
4
Insights into the Main Protease of SARS-CoV-2: Thermodynamic Analysis, Structural Characterization, and the Impact of Inhibitors.深入了解 SARS-CoV-2 的主要蛋白酶：热力学分析、结构特征及抑制剂的影响。
Anal Chem. 2024 Oct 8;96(40):15898-15906. doi: 10.1021/acs.analchem.4c02311. Epub 2024 Sep 25.
5
Biochemical and crystallographic studies of L,D-transpeptidase 2 from Mycobacterium tuberculosis with its natural monomer substrate.结核分枝杆菌 L,D-转肽酶 2 及其天然单体底物的生化和晶体学研究。
Commun Biol. 2024 Sep 18;7(1):1173. doi: 10.1038/s42003-024-06785-3.
6
Development of a new experimental NMR strategy for covalent cysteine protease inhibitors screening: toward enhanced drug discovery.用于共价半胱氨酸蛋白酶抑制剂筛选的新型实验性核磁共振策略的开发：迈向增强药物发现
RSC Adv. 2024 Aug 23;14(37):26829-26836. doi: 10.1039/d4ra04938a. eCollection 2024 Aug 22.
7
Breaking the Chain: Protease Inhibitors as Game Changers in Respiratory Viruses Management.打破链条：蛋白酶抑制剂在呼吸道病毒管理中的变革作用。
Int J Mol Sci. 2024 Jul 25;25(15):8105. doi: 10.3390/ijms25158105.
8
On the origins of SARS-CoV-2 main protease inhibitors.关于严重急性呼吸综合征冠状病毒2主要蛋白酶抑制剂的起源
RSC Med Chem. 2023 Oct 13;15(1):81-118. doi: 10.1039/d3md00493g. eCollection 2024 Jan 25.
9
αβ,α'β'-Diepoxyketones are mechanism-based inhibitors of nucleophilic cysteine enzymes.αβ,α'β'-环氧酮是亲核半胱氨酸酶的基于机制的抑制剂。
Chem Commun (Camb). 2023 Oct 26;59(86):12859-12862. doi: 10.1039/d3cc02932h.
10
High-throughput screen with the l,d-transpeptidase Ldt of reveals novel classes of covalently reacting inhibitors.对L,d-转肽酶Ldt进行高通量筛选，发现了新型共价反应抑制剂。
Chem Sci. 2023 May 30;14(26):7262-7278. doi: 10.1039/d2sc06858c. eCollection 2023 Jul 5.
本文引用的文献
1
SARS-CoV-2 M inhibitors with antiviral activity in a transgenic mouse model.具有抗病毒活性的 SARS-CoV-2 M 抑制剂在转基因小鼠模型中。
Science. 2021 Mar 26;371(6536):1374-1378. doi: 10.1126/science.abf1611. Epub 2021 Feb 18.
2
A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.一种含有吲哚结构的小分子化合物抑制 SARS-CoV-2 的主要蛋白酶并阻断病毒复制。
Nat Commun. 2021 Jan 28;12(1):668. doi: 10.1038/s41467-021-20900-6.
3
What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design.冠状病毒3C样蛋白酶告诉我们的：从结构、底物选择性到抑制剂设计
Med Res Rev. 2021 Jul;41(4):1965-1998. doi: 10.1002/med.21783. Epub 2021 Jan 18.
4
A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment.一种计算药物再利用方法，用于鉴定头孢菌素抗生素和抗丙型肝炎药物衍生物，以用于 COVID-19 治疗。
Comput Biol Med. 2021 Mar;130:104186. doi: 10.1016/j.compbiomed.2020.104186. Epub 2020 Dec 19.
5
Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors.依布硒啉、双硫仑、卡莫氟、PX-12、替德吉布和紫草素是非特异性混杂的新型冠状病毒2型主要蛋白酶抑制剂。
ACS Pharmacol Transl Sci. 2020 Oct 9;3(6):1265-1277. doi: 10.1021/acsptsci.0c00130. eCollection 2020 Dec 11.
6
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.通过定量高通量筛选鉴定新型冠状病毒3CL蛋白酶抑制剂
ACS Pharmacol Transl Sci. 2020 Sep 4;3(5):1008-1016. doi: 10.1021/acsptsci.0c00108. eCollection 2020 Oct 9.
7
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.酮基共价抑制剂冠状病毒 3CL 蛋白酶的发现，为 COVID-19 的潜在治疗提供了可能。
J Med Chem. 2020 Nov 12;63(21):12725-12747. doi: 10.1021/acs.jmedchem.0c01063. Epub 2020 Oct 15.
8
GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.GRL-0920，一种吲哚氯吡啶酯，可完全阻断 SARS-CoV-2 感染。
mBio. 2020 Aug 20;11(4):e01833-20. doi: 10.1128/mBio.01833-20.
9
Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients.双黄连制剂及生物活性成分体外抗 SARS-CoV-2 活性
Acta Pharmacol Sin. 2020 Sep;41(9):1167-1177. doi: 10.1038/s41401-020-0483-6. Epub 2020 Jul 31.
10
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.通过大规模化合物重新利用发现抗 SARS-CoV-2 病毒药物。
Nature. 2020 Oct;586(7827):113-119. doi: 10.1038/s41586-020-2577-1. Epub 2020 Jul 24.
Zotero 插件